AXGN250117C12500
- 3.05
- 0.000.00%
AxoGen Newsroom
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN), Beam Therapeutics (BEAM) and Madrigal Pharmaceuticals (MDGL)
Axogen (NASDAQ:AXGN) Delivers Shareholders Stellar 131% Return Over 1 Year, Surging 25% in the Last Week Alone
Axogen, Inc. Appoints Craig Swandal as Vice President of Operations
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | AxoGen Announces New Vp of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Axogen Sees FY 2024 Revenue of About $187.3M >AXGN
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
Express News | AxoGen Q4 Revenue USD 49.4 Million Vs. IBES Estimate USD 47.6 Million
Axogen, Inc. (NASDAQ:AXGN) Looks Just Right With A 29% Price Jump
With 78% Ownership in Axogen, Inc. (NASDAQ:AXGN), Institutional Investors Have a Lot Riding on the Business
Those Who Invested in Axogen (NASDAQ:AXGN) a Year Ago Are up 98%
Top Premarket Decliners
All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy
Is Axogen (NASDAQ:AXGN) A Risky Investment?
How Much Upside Is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18%
Top 10 Most Expensive Stocks (Only 1 Gets a Quant Sell)
Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript Summary
Insiders At Axogen Sold US$639k In Stock, Alluding To Potential Weakness
CCORF Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $17
Axogen Inc (AXGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements